TG Therapeutics, Inc. is a biopharmaceutical company. It focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.
No unusual activity trades found. Try filtering by a different expiration or applying global filters to show complex (spreads, buy-write etc) & sold on the bid trades.